Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1361

Shown on this page

Current sort

Live official records

Conditions: Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
Interventions: Not listed
Lead sponsor: CoMind Technologies Limited; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • Wilmington, Delaware + 14 more

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Sacramento, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Adalimumab Biosimilars Injection, Placebo; Drug · Other
Lead sponsor: Daniel Moriarity; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions: Botulinum Neurotoxin Type A; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Hypertension
Interventions: lorundrostat, Placebo; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 128
States / cities: Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more

Conditions: Breast Cancer
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2032
U.S. locations: 66
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Nectero EAST System; Drug
Lead sponsor: Nectero Medical, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 40
States / cities: Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
Interventions: Thoracic Aortic Surgery; Procedure
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years to 79 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 16
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more

Conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions: JNJ-79635322; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • San Francisco, California + 5 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

CoMind Early Feasibility Study

HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

Precision Depression Adalimumab Trial

DaxibotulinumtoxinA for Blepharospasm

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Understanding and Predicting Breast Cancer Events After Treatment

Nectero EAST System Clinical Study

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

About this Penn Medicine (University of Pennsylvania) institution page